Leerink Partnrs Predicts Weaker Earnings for Replimune Group

Replimune Group, Inc. (NASDAQ:REPL) – Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Replimune Group in a research note issued on Wednesday, February 12th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of ($2.93) per share for the year, down from their previous forecast of ($2.82). The consensus estimate for Replimune Group’s current full-year earnings is ($2.88) per share. Leerink Partnrs also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.69) EPS and FY2026 earnings at ($2.22) EPS.

REPL has been the subject of several other research reports. Jefferies Financial Group boosted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. HC Wainwright boosted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, BMO Capital Markets upped their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $19.29.

Replimune Group Trading Down 1.3 %

NASDAQ REPL opened at $14.10 on Monday. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a market cap of $964.72 million, a PE ratio of -4.62 and a beta of 1.30. The company has a 50 day moving average price of $12.54 and a 200 day moving average price of $11.74. Replimune Group has a 52 week low of $4.92 and a 52 week high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09).

Institutional Trading of Replimune Group

Several large investors have recently made changes to their positions in REPL. SG Americas Securities LLC purchased a new stake in shares of Replimune Group in the 3rd quarter valued at $251,000. Creative Planning boosted its holdings in shares of Replimune Group by 28.7% in the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after acquiring an additional 4,699 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Replimune Group by 82.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock valued at $144,000 after acquiring an additional 5,926 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Replimune Group in the 3rd quarter valued at $222,000. Finally, LMR Partners LLP boosted its holdings in shares of Replimune Group by 145.8% in the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock valued at $904,000 after acquiring an additional 48,920 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 8.80% of the stock is currently owned by company insiders.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.